Pyng Medical Corp. MAT(R) Tourniquet Featured in Wired Magazine’s Top 10 Designs for Good

VANCOUVER, BRITISH COLUMBIA--(Marketwire - September 03, 2009) - Pyng Medical Corp.'s (the “Company”) (TSX VENTURE: PYT) MAT® Tourniquet is being featured in the October edition of Wired UK Magazine as one of the “Top 10 Designs for Good.”

Wired is a magazine focused on the latest in new ideas, technology, business and culture. Based on the upcoming October 2009 release from Metropolis books, “Design Revolution: 100 Products That Empower People” by Emily Pilloton, Wired Magazine features the Top 10 of these 100 designs in their October UK edition.

“We are honored that Wired is featuring the MAT Tourniquet as one of the Top 10 Products Designed for Good,” comments Nadine Gaston, Vice President of Sales for Pyng. “With a significant international subscription and readership base and a mission of highlighting smart trends in technologies, Wired’s feature will spotlight the innovation of the MAT Tourniquet to a wider audience.”

Featuring a full color photo, Wired’s article draws attention to life saving benefits of the MAT. “This article, together with the inclusion in the Design Revolution book, illuminates the benefits of the MAT Tourniquet’s superior design at a time when new tourniquet protocols are being implemented world-wide,” adds Nadine.

About Wired UK Magazine

Wired is the magazine about what’s next - bringing you the people, the trends and the big ideas that will change our lives. Each month, through thought-provoking features and stunning photography, they explore the next big ideas in science, culture, business - wherever innovation and new thinking are reshaping our world.

Since the US edition of Wired launched in 1993, the magazine has been synonymous with informed and intelligent analysis, and a consistently reliable predictor of change. The UK edition, launched in April 2009, is similarly committed to bringing you the best writers and photographers; compelling long-form journalism; extraordinary photography and design; and the people, products and ideas that matter.

About Pyng Medical Corp.

Pyng Medical Corp. commercializes award-winning trauma and resuscitation products for front line critical care personnel. Creators of the FAST1® Intraosseous Infusion System, Pyng’s expanded product portfolio includes a variety of innovative, lifesaving tools including the T-POD® Pelvic Stabilizer and MAT® Tourniquet. With growing markets in North America, Europe and Asia, Pyng offers user-preferred medical devices for use by hospital staff, emergency medical services and military forces worldwide. Pyng has received the exclusive 2008 Medical Device Company of the Year Award from Life Sciences British Columbia for its sustained achievements in commercializing the Company’s proprietary FAST1®, the only medical device able to provide rapid sternal access for administering drugs and fluids to the heart in seconds. The Company was also selected in the “2007 TSX Venture 50" Top 10 companies in Life Sciences based on solid financial metrics for the year ending December 31, 2006.

Safe Harbour Statement; Forward-Looking Statements: This release may contain forward-looking statements based on management’s expectations, estimates and projections. All statements that address expectations or projections about the future, including statements about the Company’s strategy for growth, product development, market position, expected expenditures and financial results are forward-looking statements. Some of the forward-looking statements may be identified by words like “expects”, “anticipates”, “plans”, “intends”, “projects”, “indicates”, and similar expressions. These statements are not guarantees of future performance and involve a number of risks, uncertainties and assumptions. Many factors, including those discussed more fully elsewhere in this release and in documents which may be filed with the British Columbia Securities Commission, the Alberta Securities Commission, the Ontario Securities Commission, the TSX Venture Exchange, as well as other USA Commissions, could cause results to differ materially from those stated. These factors include, but are not limited to changes in the laws, regulations, policies and economic conditions, including inflation, interest and foreign currency exchange rates, of countries in which the Company does business; competitive pressures; successful integration of structural changes, including restructuring plans, acquisitions, divestitures and alliances; cost of raw material, research and development of new products, including regulatory approval and market acceptance; and seasonality of sales in some products.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.